NCT04530123: An ongoing trial by Takeda
This trial is ongoing. It must report results 9 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04530123 |
|---|---|
| Title | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-101 for the Prevention of Gluten-Specific T Cell Activation in Subjects With Celiac Disease on a Gluten-Free Diet |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 23, 2022 |
| Completion date | Jan. 8, 2026 |
| Required reporting date | Jan. 8, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |